EA201201177A1 - Димерные ингибиторы iap - Google Patents
Димерные ингибиторы iapInfo
- Publication number
- EA201201177A1 EA201201177A1 EA201201177A EA201201177A EA201201177A1 EA 201201177 A1 EA201201177 A1 EA 201201177A1 EA 201201177 A EA201201177 A EA 201201177A EA 201201177 A EA201201177 A EA 201201177A EA 201201177 A1 EA201201177 A1 EA 201201177A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- iap
- dimeric inhibitors
- dimeric
- formula
- inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000006907 apoptotic process Effects 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000000178 monomer Substances 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30811410P | 2010-02-25 | 2010-02-25 | |
| US33392710P | 2010-05-12 | 2010-05-12 | |
| US38841010P | 2010-09-30 | 2010-09-30 | |
| PCT/EP2011/052662 WO2011104266A1 (en) | 2010-02-25 | 2011-02-23 | Dimeric iap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201201177A1 true EA201201177A1 (ru) | 2013-04-30 |
Family
ID=44476672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201201177A EA201201177A1 (ru) | 2010-02-25 | 2011-02-23 | Димерные ингибиторы iap |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8445440B2 (https=) |
| EP (1) | EP2539333A1 (https=) |
| JP (1) | JP2013520466A (https=) |
| KR (1) | KR20130010894A (https=) |
| CN (1) | CN102834389A (https=) |
| AR (1) | AR080253A1 (https=) |
| BR (1) | BR112012021291A2 (https=) |
| CA (1) | CA2790302A1 (https=) |
| EA (1) | EA201201177A1 (https=) |
| MX (1) | MX2012009894A (https=) |
| TW (1) | TW201141846A (https=) |
| UY (1) | UY33236A (https=) |
| WO (1) | WO2011104266A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| UY33794A (es) * | 2010-12-13 | 2012-07-31 | Novartis Ag | Inhibidores diméricos de las iap |
| US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| US9453048B2 (en) | 2012-08-09 | 2016-09-27 | Bristol-Myers Squibb Company | IAP antagonists |
| CA2930030A1 (en) * | 2012-11-09 | 2014-05-15 | Ensemble Therapeutics Corporation | Macrocyclic compounds for inhibition of inhibitors of apoptosis |
| KR20160030099A (ko) | 2013-06-25 | 2016-03-16 | 더 월터 앤드 엘리자 홀 인스티튜트 오브 메디컬 리서치 | 세포내 감염의 치료 방법 |
| WO2016079527A1 (en) | 2014-11-19 | 2016-05-26 | Tetralogic Birinapant Uk Ltd | Combination therapy |
| WO2016097773A1 (en) | 2014-12-19 | 2016-06-23 | Children's Cancer Institute | Therapeutic iap antagonists for treating proliferative disorders |
| CN109705191B (zh) * | 2017-10-25 | 2022-04-29 | 广东东阳光药业有限公司 | Iap抑制剂及其在药物中的应用 |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US5281620A (en) | 1986-12-23 | 1994-01-25 | Cancer Research Campaign Technology Limited | Compounds having antitumor and antibacterial properties |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP2002037626A (ja) | 2000-07-27 | 2002-02-06 | Internatl Superconductivity Technology Center | ビスマス系高温超電導体の製造方法。 |
| PE20020354A1 (es) | 2000-09-01 | 2002-06-12 | Novartis Ag | Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda) |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| KR20090046973A (ko) | 2002-11-27 | 2009-05-11 | 아이알엠 엘엘씨 | 암세포에서 세포자멸사를 유도하기 위한 방법 및 조성물 |
| JP2007524596A (ja) | 2003-02-28 | 2007-08-30 | トランスフォーム・ファーマシューティカルズ・インコーポレイテッド | 共結晶医薬組成物 |
| CN1953744A (zh) | 2004-02-05 | 2007-04-25 | 诺瓦提斯公司 | Dna拓扑异构酶抑制剂和iap抑制剂的组合 |
| WO2005084317A2 (en) | 2004-03-01 | 2005-09-15 | Board Of Regents, The University Of Texas System | Dimeric small molecule potentiators of apoptosis |
| ES2475207T3 (es) | 2004-07-15 | 2014-07-10 | Tetralogic Pharmaceuticals Corporation | Compuestos de unión a IAP |
| MX2007010371A (es) | 2005-02-25 | 2008-01-11 | Tetralogic Pharmaceuticals | Inhibidores dimericos iap. |
| JP4954983B2 (ja) | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| CA2617642A1 (en) | 2005-08-09 | 2007-02-22 | Tetralogic Pharmaceuticals Corporation | Treatment of proliferative disorders |
| WO2007048224A1 (en) * | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| KR20080080131A (ko) | 2005-12-20 | 2008-09-02 | 노파르티스 아게 | Ｉａｐ-억제제와 탁산의 조합물 |
| TWI504597B (zh) | 2006-03-16 | 2015-10-21 | Pharmascience Inc | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| US7807699B2 (en) | 2006-03-21 | 2010-10-05 | Joyant Pharmaceuticals, Inc. | Dimeric pyrrolidine amide-containing small molecule apoptosis promoters |
| US8202902B2 (en) | 2006-05-05 | 2012-06-19 | The Regents Of The University Of Michigan | Bivalent SMAC mimetics and the uses thereof |
| CN101535300B (zh) | 2006-05-16 | 2014-05-28 | 埃格拉医疗公司 | Iap bir域结合化合物 |
| MX2009000824A (es) | 2006-07-24 | 2009-02-04 | Tetralogic Pharmaceuticals Cor | Antagonistas dimericos de las proteinas inhibidoras de la apoptosis. |
| WO2008014240A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100143499A1 (en) | 2006-07-24 | 2010-06-10 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| JP5452223B2 (ja) | 2006-07-24 | 2014-03-26 | テトラロジック ファーマシューティカルズ コーポレーション | Ｉａｐ阻害剤 |
| WO2008014229A2 (en) | 2006-07-24 | 2008-01-31 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| US20100056495A1 (en) | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| PE20110220A1 (es) | 2006-08-02 | 2011-04-11 | Novartis Ag | DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS |
| BRPI0717411A2 (pt) | 2006-10-19 | 2013-11-12 | Novartis Ag | Uso de inibidores de iap |
| JP2010511057A (ja) | 2006-11-28 | 2010-04-08 | ノバルティス アーゲー | 急性骨髄性白血病の処置のためのｉａｐ阻害剤の使用 |
| WO2008066854A2 (en) | 2006-11-28 | 2008-06-05 | Novartis Ag | Methods and compositions for inducing apoptosis in cancer cells |
| KR101149449B1 (ko) | 2007-03-20 | 2012-05-25 | 삼성전자주식회사 | 오디오 신호의 인코딩 방법 및 장치, 그리고 오디오 신호의디코딩 방법 및 장치 |
| JP5454943B2 (ja) | 2007-04-12 | 2014-03-26 | ジョイアント ファーマスーティカルズ、インク． | 抗癌剤として有用なｓｍａｃ模倣二量体及び三量体 |
| WO2008134679A1 (en) | 2007-04-30 | 2008-11-06 | Genentech, Inc. | Inhibitors of iap |
| JP2010528587A (ja) | 2007-05-07 | 2010-08-26 | テトラロジック ファーマシューティカルズ コーポレーション | アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法 |
| EP2205242B1 (en) | 2007-09-12 | 2015-04-15 | Genentech, Inc. | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| JP5348725B2 (ja) | 2007-10-25 | 2013-11-20 | ジェネンテック， インコーポレイテッド | チエノピリミジン化合物の製造方法 |
| EP2058312A1 (en) | 2007-11-09 | 2009-05-13 | Universita' degli Studi di Milano | SMAC mimetic compounds as apoptosis inducers |
| AU2009203971A1 (en) | 2008-01-11 | 2009-07-16 | Genentech, Inc. | Inhibitors of IAP |
| CA2712604A1 (en) | 2008-01-24 | 2009-07-30 | Tetralogic Pharmaceutical Corporation | Iap inhibitors |
| WO2009136290A1 (en) | 2008-05-05 | 2009-11-12 | Aegera Therapeutics, Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| AU2009261919A1 (en) | 2008-06-27 | 2009-12-30 | Pharmascience Inc. | Bridged secondary amines and use thereof as IAP BIR domain binding compounds |
| JP2011529962A (ja) | 2008-08-02 | 2011-12-15 | ジェネンテック， インコーポレイテッド | Ｉａｐのインヒビター |
| US20120009141A1 (en) | 2008-08-07 | 2012-01-12 | Pharmascience Inc. | Functionalized pyrrolidines and use thereof as iap inhibitors |
| WO2010033531A1 (en) | 2008-09-17 | 2010-03-25 | Tetralogic Pharmaceuticals Corp. | Iap inhibitors |
| WO2010033315A1 (en) | 2008-09-22 | 2010-03-25 | Amgen Inc. | Method of treatment |
| US8283372B2 (en) | 2009-07-02 | 2012-10-09 | Tetralogic Pharmaceuticals Corp. | 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic |
-
2011
- 2011-02-21 UY UY0001033236A patent/UY33236A/es not_active Application Discontinuation
- 2011-02-23 EP EP11705532A patent/EP2539333A1/en not_active Withdrawn
- 2011-02-23 MX MX2012009894A patent/MX2012009894A/es active IP Right Grant
- 2011-02-23 CA CA2790302A patent/CA2790302A1/en not_active Abandoned
- 2011-02-23 AR ARP110100547A patent/AR080253A1/es unknown
- 2011-02-23 JP JP2012554332A patent/JP2013520466A/ja active Pending
- 2011-02-23 BR BR112012021291A patent/BR112012021291A2/pt not_active IP Right Cessation
- 2011-02-23 WO PCT/EP2011/052662 patent/WO2011104266A1/en not_active Ceased
- 2011-02-23 KR KR1020127024875A patent/KR20130010894A/ko not_active Withdrawn
- 2011-02-23 EA EA201201177A patent/EA201201177A1/ru unknown
- 2011-02-23 US US13/033,463 patent/US8445440B2/en not_active Expired - Fee Related
- 2011-02-23 CN CN2011800177078A patent/CN102834389A/zh active Pending
- 2011-02-24 TW TW100106289A patent/TW201141846A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20130010894A (ko) | 2013-01-29 |
| CA2790302A1 (en) | 2011-09-01 |
| JP2013520466A (ja) | 2013-06-06 |
| AU2011219862A1 (en) | 2012-09-06 |
| EP2539333A1 (en) | 2013-01-02 |
| BR112012021291A2 (pt) | 2016-10-25 |
| WO2011104266A1 (en) | 2011-09-01 |
| MX2012009894A (es) | 2012-09-12 |
| TW201141846A (en) | 2011-12-01 |
| CN102834389A (zh) | 2012-12-19 |
| US8445440B2 (en) | 2013-05-21 |
| UY33236A (es) | 2011-09-30 |
| AR080253A1 (es) | 2012-03-21 |
| US20110206690A1 (en) | 2011-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201201177A1 (ru) | Димерные ингибиторы iap | |
| JOP20180104A1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| JOP20180103A1 (ar) | مركب صيدلاني | |
| EA201491412A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| UA110354C2 (uk) | Противірусні сполуки | |
| EA201491766A1 (ru) | Соединения для лечения спинальной мышечной атрофии | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201491786A1 (ru) | ТРИАЗОЛОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ mPGES-1 | |
| JO3131B1 (ar) | مركبات كيميائية | |
| EA201590005A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
| EA201692166A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
| UA115231C2 (uk) | Сполуки імідазопіролідинонів | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| TR201816379T4 (tr) | DNA-PK inhibitörleri. | |
| EA201691354A1 (ru) | Терапевтические ингибирующие соединения | |
| EA201400412A1 (ru) | ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ | |
| EA201390609A1 (ru) | ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ | |
| JO3515B1 (ar) | مثبطات fgfr4 بيريميدين | |
| EA201492002A1 (ru) | Противовирусные соединения | |
| EA201491151A1 (ru) | Соединения, ингибирующие металлоферменты | |
| EA201391390A1 (ru) | Циклопропиламины в качестве ингибиторов lsd | |
| EA201291357A1 (ru) | Способы лечения с применением ингибиторов tlr7 и/или tlr9 | |
| EA201490423A1 (ru) | СПОСОБЫ И КОМПОЗИЦИИ, ОТНОСЯЩИЕСЯ К p62, ДЛЯ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ РАКА | |
| EA201691574A1 (ru) | Конденсированное бициклическое 2,4-диаминопиримидиновое производное в качестве двойного alk и fak ингибитора | |
| EA201201661A1 (ru) | Новые аминопиразолохиназолины |